Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Photos from a project conducted in collaboration with photographer Pearl Gan at EOCRU in Jakarta, Indonesia were published last week in the Lancet. The See Malaria in Asia Project aims to raise public awareness of malaria as a serious health problem for the region by telling the human story of Asia’s invisible malaria burden.

CTMGH logo for News

Photos from a project conducted in collaboration with photographer Pearl Gan at EOCRU in Jakarta, Indonesia were published last week in the Lancet. The See Malaria in Asia Project aims to raise public awareness of malaria as a serious health problem for the region by telling the human story of Asia’s invisible malaria burden.

Most malaria in Asia occurs among the rural poor, who do not yet live among the benefits of the profound economic progress that the region has seen. These populations are often “invisible”, not only in an epidemiological sense but also in social terms. And therefore communities who are engaged with the global malaria problem do not see all those affected by malaria in Asia.

Funded by the Wellcome Trust, this photography project aims to engage the public with exhibitions later in the year in Jakarta, Singapore, Phnomh Penh and Ho Chi Minh City. While working on the project, photographer Pearl Gan visited remote communities where endemic malaria causes illness and deaths.  EOCRU Director Prof Kevin Baird says, “Pearl Gan captures much in her art – humanity, dignity, suffering. Her lens exposes the reality of the isolation and poverty that give malaria such freedom of harm and constraint of human development.”

The full story is available on the OUCRU website

Similar stories

Oxford and Oracle partner to speed identification of COVID-19 variants

The fast spread of the highly infectious Delta variant underscores the need for faster identification of COVID-19 mutations. Uniting governments and medical communities in this challenge, the University of Oxford and Oracle’s Global Pathogen Analysis System (GPAS) is now being used by organizations on nearly every continent. Institutions using the platform include OUCRU in Vietnam and institutions in Canada, Chile, Australia and the UK. GPAS is also now part of the Public Health England New Variant Assessment Platform.

Congratulations new Associate Professors

Following the meeting of the Medical Sciences Divisional Committee to consider applications for the conferral of the title of Associate Professor, we are pleased to announce that Rashan Haniffa, Dorcas Kamuya, Isabella Oyier, Le Van Tan and Timothy Walker have been awarded the title Associate Professor

OUCRU scientists identify combination of biological markers associated with severe dengue

Nguyen Lam Vuong, Sophie Yacoub & colleagues have identified a combination of biological markers in patients with dengue that could predict whether they go on to develop moderate to severe disease. Biomarkers are used to identify the state or risk of a disease in patients; these findings could aid the development of biomarker panels for clinical use and help improve triage and risk prediction in patients with dengue.

What does the Oxford Malaria vaccine mean for Asia?

A trial in infants and toddlers in Burkina Faso showed that experimental malaria vaccine R21/MM confers 77% protection, an unprecedented level and the first malaria vaccine to exceed WHO’s goal of 75% efficacy. While a larger trial is needed to assess its safety and efficacy, R21/MM may substantially reduce child mortality in Sub-Saharan Africa. But this vaccine may be less relevant to Asia Pacific where malaria causes severe morbidity and mortality in all age groups, asymptomatic malaria infections are frequent, and the vaccine may not be effective against P. vivax.

RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that the investigational antibody combination developed by Regeneron reduces the risk of death when given to patients hospitalised with severe COVID-19 who have not mounted a natural antibody response of their own.

Professors Peter Horby and Guy Thwaites recognised in Queen’s Birthday Honours

The pioneering work of members of the University of Oxford has been recognised in The Queen's Birthday Honours List. The honorands include Professor Peter Horby and six researchers that have played key roles in leading the University’s response to the Coronavirus pandemic, from the development of new vaccines to the discovery of new drug treatments. Professor Guy Thwaites is appointed a Member of the Order of the British Empire.